Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (SLDB), focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences.
The company will present at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 2:15 pm ET, featuring President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks. A live webcast will be available on the company's website with a 90-day replay period.
Additionally, management will conduct one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 17, 2025. Institutional investors can arrange meetings through their Needham or Piper Sandler representatives.
Solid Biosciences (SLDB), focalizzata nello sviluppo di medicinali genetici di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione a due prossime conferenze per investitori.
L'azienda presenterà al 24° Annual Needham Virtual Healthcare Conference il 10 aprile 2025, alle 14:15 ET, con la partecipazione del Presidente e CEO Bo Cumbo e del Chief Medical Officer Gabriel Brooks. Sarà disponibile un webcast dal vivo sul sito web dell'azienda con un periodo di replay di 90 giorni.
Inoltre, la direzione condurrà incontri individuali al Piper Sandler Spring Biopharma Symposium a Boston, MA, il 17 aprile 2025. Gli investitori istituzionali possono organizzare incontri tramite i loro rappresentanti di Needham o Piper Sandler.
Solid Biosciences (SLDB), enfocada en desarrollar medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado su participación en dos próximas conferencias para inversores.
La empresa presentará en la 24ª Conferencia Virtual de Salud de Needham el 10 de abril de 2025, a las 2:15 p. m. ET, con la participación del Presidente y CEO Bo Cumbo y del Director Médico Gabriel Brooks. Habrá una transmisión en vivo disponible en el sitio web de la empresa con un periodo de repetición de 90 días.
Además, la dirección llevará a cabo reuniones individuales en el Símbolo de Biopharma de Primavera de Piper Sandler en Boston, MA, el 17 de abril de 2025. Los inversores institucionales pueden organizar reuniones a través de sus representantes de Needham o Piper Sandler.
솔리드 바이오사이언스(슬디비)는 신경근육 및 심장 질환을 위한 정밀 유전자 의약품 개발에 주력하고 있으며, 두 개의 다가오는 투자자 회의에 참여할 것이라고 발표했습니다.
회사는 2025년 4월 10일 동부 표준시 기준 오후 2시 15분에 제24회 니드햄 가상 의료 회의에서 발표할 예정이며, 보 콤보 대통령 겸 CEO와 가브리엘 브룩스 최고 의학 책임자가 참석합니다. 회사 웹사이트에서 생중계가 제공되며, 90일 간 재생할 수 있습니다.
추가로, 경영진은 2025년 4월 17일 매사추세츠주 보스턴에서 열리는 파이퍼 샌들러 봄 생명과학 심포지엄에서 개별 회의를 진행할 예정입니다. 기관 투자자들은 니드햄 또는 파이퍼 샌들러 대표를 통해 회의를 예약할 수 있습니다.
Solid Biosciences (SLDB), axée sur le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé sa participation à deux prochaines conférences pour investisseurs.
L'entreprise présentera lors de la 24e Conférence Virtuelle de Santé de Needham le 10 avril 2025, à 14h15 ET, avec la participation du Président et CEO Bo Cumbo et du Directeur Médical Gabriel Brooks. Une diffusion en direct sera disponible sur le site web de l'entreprise avec une période de rediffusion de 90 jours.
De plus, la direction organisera des réunions individuelles lors du Séminaire Printanier de Biopharma de Piper Sandler à Boston, MA, le 17 avril 2025. Les investisseurs institutionnels peuvent organiser des réunions par l'intermédiaire de leurs représentants de Needham ou Piper Sandler.
Solid Biosciences (SLDB), das sich auf die Entwicklung von präzisen genetischen Medikamenten für neuromuskuläre und Herzkrankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird am 24. Annual Needham Virtual Healthcare Conference am 10. April 2025 um 14:15 Uhr ET präsentieren, mit Präsident und CEO Bo Cumbo sowie Chief Medical Officer Gabriel Brooks. Eine Live-Übertragung wird auf der Website des Unternehmens verfügbar sein, mit einer 90-tägigen Wiederholungszeit.
Darüber hinaus wird das Management Einzelgespräche beim Piper Sandler Spring Biopharma Symposium in Boston, MA, am 17. April 2025 führen. Institutionelle Investoren können über ihre Vertreter von Needham oder Piper Sandler Meetings vereinbaren.
- None.
- None.
CHARLESTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- 24th Annual Needham Virtual Healthcare Conference
Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present on Thursday, April 10, 2025, at 2:15 pm ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page.
- Piper Sandler Spring Biopharma Symposium – Boston, MA
Management will participate in one-on-one meetings on Thursday, April 17, 2025.
Institutional investors interested in meeting with management during the conference may reach out to their Needham or Piper Sandler representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Solid Biosciences (SLDB) presenting at the Needham Healthcare Conference 2025?
How long will SLDB's Needham Conference webcast be available for replay?
Which executives from SLDB are presenting at the Needham Healthcare Conference?
When is Solid Biosciences participating in the Piper Sandler Spring Biopharma Symposium?
What type of medicines is Solid Biosciences (SLDB) developing?
